Celularity (Celularity) Inventory-to-Revenue : 1.41 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Celularity Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Celularity's Average Total Inventories for the quarter that ended in Sep. 2023 was $5.34 Mil. Celularity's Revenue for the three months ended in Sep. 2023 was $3.79 Mil. Celularity's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 1.41.

Celularity's Inventory-to-Revenue for the quarter that ended in Sep. 2023 declined from Jun. 2023 (1.91) to Jun. 2023 (1.41)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Celularity's Days Inventory for the three months ended in Sep. 2023 was 135.18.

Inventory Turnover measures how fast the company turns over its inventory within a year. Celularity's Inventory Turnover for the quarter that ended in Sep. 2023 was 0.68.

Celularity Inventory-to-Revenue Historical Data

The historical data trend for Celularity's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Inventory-to-Revenue Chart

Celularity Annual Data

Trend

Dec20

Dec21

Dec22

Inventory-to-Revenue

0.27

0.31

0.41

Celularity Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Inventory-to-Revenue	Get a 7-Day Free Trial									3.62	1.28	1.37	1.91	1.41

Competitive Comparison of Celularity's Inventory-to-Revenue

For the Biotechnology subindustry, Celularity's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celularity's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Celularity's Inventory-to-Revenue falls into.

Celularity Inventory-to-Revenue Calculation

Celularity's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (A: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )
=	( (9.549	+	5.308)	/	2 )	/	17.975
=	7.4285					/	17.975
=	0.41

Celularity's Inventory-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

	Inventory-to-Revenue (Q: Sep. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Sep. 2023 ))	/	count )	/	Revenue (Q: Sep. 2023 )
=	( (5.738	+	4.934)	/	2 )	/	3.786
=	5.336					/	3.786
=	1.41

Celularity (NAS:CELU) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Celularity's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2023 )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
	=	5.336	/	3.602	*	365 / 4
	=	135.18

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Celularity's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2023 )	/	Average Total Inventories (Q: Sep. 2023 )
	=	3.602	/	5.336
	=	0.68

Celularity Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Celularity's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Celularity (Celularity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

170 Park Avenue, Florham Park, NJ, USA, 07932

Website

https://www.celularity.com

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Executives

Kok Thay Lim	director	22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri	director, officer: Chief Executive Officer	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d.	director	C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting	10 percent owner	24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne	officer: See Remarks	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher	officer: General Counsel	CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler	director	C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur	director	31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover	director, officer: Chief Technology Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido	officer: Pres, Functional Regeneration	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones	director, officer: Chief Business Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932